GW590735

Research use only, not for human use.

GW590735 is an effective and selective PPARα agonist with an EC50 of 4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW590735 can be used in dyslipidemia studies.

GW590735 is an effective and selective PPARα agonist with an EC50 of 4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW590735 can be used in dyslipidemia studies.(In Vivo):GW590735 (2 mg/kg; i.v.) shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively in dogs while GW590735 (2.7 mg/kg; i.v.) shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively in rats. In male C57BL/6 mice transgenic for human ApoA-I, GW590735 (0.5-5 mg/kg; oral) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol.

——

GW 590735 (0.5-5 mg/kg; orally twice a day for 5 days) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol in the Apo-A-I-transgenic mouse model (male C57BL/6 mice transgenic for human ApoA-I).GW 590735 (intravenous administration; 2.7 mg/kg; rat) treatment shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively.GW 590735 (intravenous administration; 2 mg/kg; dog) treatment shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively.

——

Metabolic Enzyme/Protease

PPAR

norepinephrine|nAChR

——

——

343321-96-0

478.48

C23H21F3N2O4S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (522.49 mM)

CC(C)(C(O)=O)Oc1ccc(CNC(c2c(C)nc(-c3ccc(C(F)(F)F)cc3)s2)=O)cc1

——

(-20℃)

With Ice Pack

≥ 2 years